ERBB2 and lung carcinoma: In addition to EGFR inhibition, there is clinical evidence that inhibiting MET amplification,15, 16, 17 ERBB2 amplification,18 BRAF mutation,19 rearranged during transfection (RET) fusion,11, 20 and anaplastic lymphoma kinase (ALK) fusion12 may be effective in controlling EGFR‐TKI‐resistant lung cancers.